Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on February 27 and 28, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock on February 27, 2025, at a weighted average price of $11.33 per share.
• He also sold 2,000 shares of common stock on February 28, 2025, at a weighted average price of $11.41 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Ma indirectly owns 2,851,260 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Sales by company presidents are common and are often pre-planned to avoid insider trading accusations. The use of a 10b5-1 plan indicates the sales were arranged in advance.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates